Onkológia 3/2007

COMPLETE REMISION AFTER CETUXIMAB WITH IRINOTECAN IN COMBINATION WITH SURGICAL TREATMENT IN PRETREATED PATIENT (CASE REPORT)

Colorectal cancer is one of the most prevalent cancers in Europe. Approximately 25 % of cases present with metastatic disease. If resectable, 5-year survival rates for patients with metastatic disease varies from 5 – 40 %. A multidisciplinary approach is important in the treatment of metastatic colorectal cancer (mCRC) patients with liver metastases. Cetuximab is highly effective in patients with mCRC who have failed irinotecan-based therapy. Our case demonstrates the efficacy of cetuximab plus irinotecan in pretreated patient with mCRC resulting in R0 resection of the relapsed metastatic disease.

Keywords: cetuximab (Erbitux), irinotecan, complete remision.